The molecular glue degrader medicines furthest along in development are potential cancer treatments, but Monte Rosa Therapeutics is also researching how this therapeutic modality can treat ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Monte Rosa Therapeutics (GLUE) reports results for the quarter ended December 2025. While this widely-known consensus ...

Clinical update and financing reshape Monte Rosa Therapeutics (GLUE) story Monte Rosa Therapeutics (GLUE) is back in focus after updated Phase 1/2 data for MRT-2359 in metastatic castration-resistant ...

Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal worth up to $5.7bn. The agreement will see Novartis pay ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Monte Rosa Therapeutics recently reported updated Phase 1/2 data showing that its investigational GSPT1 degrader MRT-2359, in combination with enzalutamide, was well-tolerated and produced positive ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...